1. Home
  2. UCAR vs SNTI Comparison

UCAR vs SNTI Comparison

Compare UCAR & SNTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo U Power Limited

UCAR

U Power Limited

HOLD

Current Price

$1.10

Market Cap

35.5M

ML Signal

HOLD

Logo Senti Biosciences Inc.

SNTI

Senti Biosciences Inc.

HOLD

Current Price

$0.43

Market Cap

31.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UCAR
SNTI
Founded
2013
2016
Country
China
United States
Employees
N/A
N/A
Industry
Retail-Auto Dealers and Gas Stations
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.5M
31.5M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
UCAR
SNTI
Price
$1.10
$0.43
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$50.00
$8.50
AVG Volume (30 Days)
245.8K
147.3K
Earning Date
05-15-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
77.31
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.04
$0.42
52 Week High
$4.60
$2.88

Technical Indicators

Market Signals
Indicator
UCAR
SNTI
Relative Strength Index (RSI) 39.10 20.14
Support Level $0.04 N/A
Resistance Level $1.68 $1.02
Average True Range (ATR) 0.10 0.09
MACD -0.00 -0.08
Stochastic Oscillator 10.00 0.45

Price Performance

Historical Comparison
UCAR
SNTI

About UCAR U Power Limited

U Power Ltd is involved in the provision of vehicle sourcing services. It is principally engaged in the provision of new energy vehicles development and sales; battery swapping stations manufacturing and sales; battery swapping services, and sourcing services. The company, as a broker, engaged in sales of vehicles between automobile wholesalers and buyers, including small and medium-sized vehicle dealers and individual customers located in lower-tier cities in China.

About SNTI Senti Biosciences Inc.

Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).

Share on Social Networks: